1,128
Views
3
CrossRef citations to date
0
Altmetric
Short Communication

Activation of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with amines and amino acids

ORCID Icon, , , ORCID Icon & ORCID Icon
Pages 758-763 | Received 22 Jan 2021, Accepted 25 Feb 2021, Published online: 10 Mar 2021

References

  • (a) D’Ambrosio K, Supuran CT, De Simone G. Are carbonic anhydrases suitable targets to fight protozoan parasitic diseases? Curr Med Chem 2018;25:5266–78. (b) Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704. (c) Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. Curr Pharm Des 2008;14:631–40. (d) Packard RM. The origins of antimalarial-drug resistance. N Engl J Med 2014;371:397–9.
  • (a) Vermelho AB, Rodrigues GC, Supuran CT. Why hasn’t there been more progress in new Chagas disease drug discovery? Expert Opin Drug Discov 2020;15:145–58. (b) Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem 2013;56:1761–71.
  • (a) Garcia AR, Oliveira DMP, Claudia F Amaral A, et al. Leishmania infantum arginase: biochemical characterization and inhibition by naturally occurring phenolic substances. J Enzyme Inhib Med Chem 2019;34:1100–9. (b) Syrjanen L, Vermelho AB, Rodrigues Ide A, et al. Cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Leishmania donovani chagasi, the protozoan parasite responsible for leishmaniasis. J Med Chem 2013;56:7372–81.
  • (a) Küng E, Fürnkranz U, Walochnik J. Chemotherapeutic options for the treatment of human trichomoniasis. Int J Antimicrob Agents 2019;53:116–27. (b) Alessio C, Nyirjesy P. Management of resistant trichomoniasis. Curr Infect Dis Rep 2019;21:31.
  • (a) Angeli A, Etxebeste-Mitxeltorena M, Sanmartín C, et al. Tellurides bearing sulfonamides as novel inhibitors of leishmanial carbonic anhydrase with potent antileishmanial activity. J Med Chem 2020;63:4306–14. (b) Nocentini A, Osman SM, Almeida IA, et al. Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani. J Enzyme Inhib Med Chem 2019;34:1164–71. (c) da Silva Cardoso V, Vermelho AB, Ricci Junior E, et al. Antileishmanial activity of sulphonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species. J Enzyme Inhib Med Chem 2018;33:850–7.
  • (a) Vermelho AB, da Silva Cardoso V, Ricci Junior E, et al. Nanoemulsions of sulfonamide carbonic anhydrase inhibitors strongly inhibit the growth of Trypanosoma cruzi. J Enzyme Inhib Med Chem 2018;33:139–46. (b) Vermelho AB, Capaci GR, Rodrigues IA, et al. Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets. Bioorg Med Chem 2017;25:1543–55. (c) Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzyme Inhib Med Chem 2018;33:286–9.
  • (a) Bua S, Haapanen S, Kuuslahti M, et al. Activation studies of the β-carbonic anhydrase from the pathogenic protozoan Entamoeba histolytica with amino acids and amines. Metabolites 2019;9:26. (b) Angeli A, Donald WA, Parkkila S, Supuran CT. Activation studies with amines and amino acids of the β-carbonic anhydrase from the pathogenic protozoan Leishmania donovani chagasi. Bioorg Chem 2018;78:406–10.
  • (a) Supuran CT. Carbonic anhydrase activators. Future Med Chem 2018;10:561–73. (b) Blandina P, Provensi G, Passsani MB, et al. Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders. J Enzyme Inhib Med Chem 2020;35:1206–14. (c) Schmidt SD, Costa A, Rani B, et al. The role of carbonic anhydrases in extinction of contextual fear memory. Proc Natl Acad Sci USA 2020;117:16000–8.
  • (a) Urbański LJ, Di Fiore A, Azizi L, et al. Biochemical and structural characterisation of a protozoan beta-carbonic anhydrase from Trichomonas vaginalis. J Enzyme Inhib Med Chem 2020;35:1292–9. (b) Urbański LJ, Angeli A, Hytönen VP, et al. Inhibition of the newly discovered β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with inorganic anions and small molecules. J Inorg Biochem 2020;213:111274.
  • Urbański LJ, Angeli A, Hytönen VP, et al. Inhibition of the β-carbonic anhydrase from the protozoan pathogen Trichomonas vaginalis with sulphonamides. J Enzyme Inhib Med Chem 2021;36:329–34.
  • (a) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81. (b) Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016; 473:2023–32. (c) Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
  • (a) Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:25. (b) Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86. (c) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60. (d) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev 2020;40:2485–565.
  • (a) Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68. (b) Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88. (c) Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov 2019;14:1175–97. (d) Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:759–72.
  • (a) Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat 2020;30:963–82. (b) Nocentini A, Del Prete S, Mastrolorenzo MD, et al. Activation studies of the β-carbonic anhydrases from Escherichia coli with amino acids and amines. J Enzyme Inhib Med Chem 2020;35:1379–86. (c) Lotlikar SR, Kayastha BB, Vullo D, et al. Pseudomonas aeruginosa β-carbonic anhydrase, psCA1, is required for calcium deposition and contributes to virulence. Cell Calcium 2019;84:102080.
  • Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
  • (a) Del Prete S, Bua S, Supuran CT, Capasso C. Escherichia coliγ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem 2020;35:1545–54. (b) Del Prete S, De Luca V, Bua S, et al. The effect of substituted benzene-sulfonamides and clinically licensed drugs on the catalytic activity of CynT2, a carbonic anhydrase crucial for Escherichia coli life cycle. Int J Mol Sci 2020;21:4175. (c) Angeli A, Ferraroni M, Pinteala M, et al. Crystal structure of a tetrameric type II β-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei. Molecules 2020; 25:2269.
  • (a) Del Prete S, Nocentini A, Supuran CT, Capasso C. Bacterial ι-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem 2020;35:1060–8. (b) Gitto R, De Luca L, Mancuso F, et al. Seeking new approach for therapeutic treatment of cholera disease via inhibition of bacterial carbonic anhydrases: experimental and theoretical studies for sixteen benzenesulfonamide derivatives. J Enzyme Inhib Med Chem 2019;34:1186–92. (c) Angeli A, Pinteala M, Maier SS, et al. Inhibition of α-, β-, γ-, δ-, ζ- and η-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine. J Enzyme Inhib Med Chem 2019;34:644–50. (d) Supuran CT, Nicolae A, Popescu A. Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes. Eur J Med Chem 1996;31:431–8.
  • (a) Angeli A, Del Prete S, Alasmary FAS, et al. The first activation studies of the η-carbonic anhydrase from the malaria parasite Plasmodium falciparum with amines and amino acids. Bioorg Chem 2018;80:94–8. (b) Angeli A, Buonanno M, Donald WA, et al. The zinc – but not cadmium – containing ζ-carbonic from the diatom Thalassiosira weissflogii is potently activated by amines and amino acids. Bioorg Chem 2018;80:261–5. (c) Angeli A, Del Prete S, Osman SM, et al. Activation studies of the γ-carbonic anhydrases from the antarctic marine bacteria Pseudoalteromonas haloplanktis and Colwellia psychrerythraea with amino acids and amines. Marine Drugs 2019;17:238–46. (d) Angeli A, Alasmary FAS, Del Prete S, et al. The first activation study of a δ-carbonic anhydrase: TweCAδ from the diatom Thalassiosira weissflogii is effectively activated by amines and amino acids. J Enzyme Inhib Med Chem 2018;33:680–5.
  • (a) Vullo D, Del Prete S, Osman SM, et al. Burkholderia pseudomallei γ-carbonic anhydrase is strongly activated by amino acids and amines. Bioorg Med Chem Lett 2017;27:77–80. (b) Vullo D, Del Prete S, Osman SM, et al. Comparison of the amine/amino acid activation profiles of the β- and γ-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei. J Enzyme Inhib Med Chem 2018;33:25–30. (c) Angeli A, Del Prete S, Osman SM, et al. Activation studies with amines and amino acids of the β-carbonic anhydrase encoded by the Rv3273 gene from the pathogenic bacterium Mycobacterium tuberculosis. J Enzyme Inhib Med Chem 2018;33:364–9.
  • (a) Nguyen GTH, Tran TN, Podgorski MN, et al. Nanoscale ion emitters in native mass spectrometry for measuring ligand-protein binding affinities. ACS Cent Sci 2019;5:308–18. (b) Nguyen GTH, Nocentini A, Angeli A, et al. Perfluoroalkyl substances of significant environmental concern can strongly inhibit human carbonic anhydrase isozymes. Anal Chem 2020;92:4614–22.
  • Covarrubias AS, Bergfors T, Jones TA, et al. Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem 2006; 281:4993–9.
  • Jin S, Vullo D, Bua S, et al. Structural and biochemical characterization of novel carbonic anhydrases from Phaeodactylum tricornutum. Acta Crystallogr D Struct Biol 2020;76:676–86.
  • Kimber MS, Pai EF. The active site architecture of Pisum sativum beta-carbonic anhydrase is a mirror image of that of alpha-carbonic anhydrases. Embo J 2000;19:1407–18.
  • (a) Briganti F, Mangani S, Orioli P, et al. Carbonic anhydrase activators: x-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry 1997;36:10384–92. (b) Temperini C, Scozzafava A, Vullo D, et al. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry 2006;12:7057–66. (c) Temperini C, Scozzafava A, Vullo D, et al. Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem 2006;49:3019–27. (d) Akocak S, Supuran CT. Activation of α-, β-, γ- δ-, ζ- and η- class of carbonic anhydrases with amines and amino acids: a review. J Enzyme Inhib Med Chem 2019;34:1652–9.